METAvivor funds research that specifically addresses the mechanistic understanding, diagnosis, and/or treatment of metastatic breast cancer. All individuals with a clinical doctoral degree or with a doctoral degree who are actively engaged in areas of metastatic breast cancer research and treatment are eligible to apply.
The 2019 grant cycle is now open at https://metavivor.infoready4.com/. This year METAvivor is offering three awards focused on treating established breast cancer metastases to improve outcomes for stage IV metastatic breast cancer patients:
In honor of METAvivor's 10-year anniversary, the METAvivor Founders Grant Award is offered for established investigators. Preference will be for advanced research projects with more well-established models, biomarkers, treatments, etc. A total of $250,000 is awarded for year 1. Second year funding is contingent upon year 1 progress report approval by METAvivor.
METAvivor Research Award (MRA) is a 2-year, $200,000 grant for established investigators. A total of $100,000 is awarded for year 1. Second year funding is contingent upon year 1 progress report approval by METAvivor. Required Letter of Intent due April 17, 2018 and invited applications due August 6, 2018.
METAvivor Early Career Investigator Award (ECIA) is a 1-year, $50,000 award available to early career applicants (investigators within 6 years of starting their first non-tenured position or within 10 years of receiving their professional degree). Required Letter of Intent due April 16, 2018 and invited applications due August 6, 2018.
Full award information, application details, and eligibility requirements can be found in the RFPs posted in the grant application portal at https://metavivor.infoready4.com/.
Thank you for your interest and participation.